Review: taking Imuran and Enbrel together


Summary

Drug interactions are reported among people who take Imuran and Enbrel together. This review analyzes the effectiveness and drug interactions between Imuran and Enbrel. It is created by eHealthMe based on reports of 1,149 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Imuran and Enbrel >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Imuran

Imuran has active ingredients of azathioprine. It is often used in crohn's disease. (latest outcomes from Imuran 9,603 users)

Enbrel

Enbrel has active ingredients of etanercept. It is often used in rheumatoid arthritis. (latest outcomes from Enbrel 172,637 users)

On Jul, 20, 2016

1,149 people who take Imuran, Enbrel are studied.


Number of reports submitted per year:

Imuran and Enbrel drug interactions.

Drug effectiveness over time:

Imuran:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 50.0% - (1 of 2 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Enbrel:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 100.0% - (2 of 2 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Imuran:
  • female: 50.0% - (1 of 2 people)
  • male: 0.0% - (0 of 1 people)
Enbrel:
  • female: 50.0% - (2 of 4 people)
  • male: 0.0% - (0 of 1 people)

Drug effectiveness by age:

Imuran:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 1 people)
  • 60+: 0.0% - (0 of 1 people)
Enbrel:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 50.0% - (1 of 2 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • dyspnoea
  • inflammation
  • pain
  • asthenia
  • pain in extremity
  • rash
  • arrhythmia
  • arteriosclerosis coronary artery
  • arthralgia
  • arthritis infective
1 - 6 months:
  • drug ineffective
  • squamous cell carcinoma of skin
  • renal failure
  • leukopenia
  • neutropenia
  • failure to thrive
  • mouth ulceration
  • ovarian epithelial cancer
  • skin cancer
  • squamous cell carcinoma
6 - 12 months:
  • nausea
  • pyrexia
  • activities of daily living impaired
  • arthritis
  • blepharospasm
  • diarrhoea
  • diplopia
  • eyelid disorder
  • eyelid ptosis
  • joint swelling
1 - 2 years:
  • failure to thrive
  • impaired healing
  • arthralgia
  • arthritis
  • drug ineffective
  • renal failure chronic
  • systemic lupus erythematosus
  • abscess limb
  • convulsion
  • diverticulitis
2 - 5 years:
  • arthralgia
  • convulsion
  • ovarian epithelial cancer
  • red blood cell sedimentation rate increased
  • arthritis
  • non-hodgkin's lymphoma
  • renal failure chronic
  • rheumatoid arthritis
  • asthenia
  • diarrhoea
5 - 10 years:
  • ganglioneuroma
  • pyrexia
  • weight decreased
  • chest pain
  • cholestasis
  • hepatic steatosis
  • steatorrhoea
  • biliary cirrhosis primary
  • bronchitis
  • cardiac failure congestive
10+ years:
  • anal fistula
  • anal ulcer
  • cardiomyopathy
  • diffuse large b-cell lymphoma
  • haemorrhoids
  • influenza like illness
  • interstitial lung disease
  • lung disorder
  • lung neoplasm
  • salivary gland neoplasm
not specified:
  • pyrexia
  • nausea
  • injection site pain
  • rheumatoid arthritis
  • fatigue
  • pain
  • drug ineffective
  • oedema peripheral
  • arthralgia
  • diarrhoea

Most common drug interactions by gender *:

female:
  • pyrexia
  • nausea
  • diarrhoea
  • rheumatoid arthritis
  • injection site pain
  • drug ineffective
  • fatigue
  • oedema peripheral
  • arthralgia
  • weight decreased
male:
  • pain
  • arthralgia
  • drug ineffective
  • dyspnoea
  • arthritis
  • rheumatoid arthritis
  • nausea
  • psoriasis
  • failure to thrive
  • fatigue

Most common drug interactions by age *:

2-9:
  • histiocytosis haematophagic
  • immunosuppression
  • parvovirus infection
  • activated partial thromboplastin time prolonged
  • blood urea increased
  • fibrin d dimer increased
  • haematocrit decreased
  • haemoglobin decreased
  • parvovirus b19 serology positive
  • white blood cell count decreased
10-19:
  • convulsion
  • lymphoma
  • lymphomatoid papulosis
  • mycobacterium avium complex infection
  • pyrexia
  • haemangioma
  • lung consolidation
  • drug ineffective
  • disseminated intravascular coagulation
  • hepatorenal failure
20-29:
  • furuncle
  • immunodeficiency
  • asthenia
  • hypotension
  • injection site erythema
  • injection site pruritus
  • injection site reaction
  • injection site swelling
  • transient ischaemic attack
  • adult respiratory distress syndrome
30-39:
  • pyrexia
  • headache
  • alopecia
  • pulmonary oedema
  • respiratory tract infection
  • uterine infection
  • leukopenia
  • constipation
  • irritability
  • oropharyngeal pain
40-49:
  • pyrexia
  • drug ineffective
  • nausea
  • arthralgia
  • injection site haemorrhage
  • arthritis
  • pain
  • ecchymosis
  • ovarian epithelial cancer
  • red blood cell sedimentation rate increased
50-59:
  • oedema peripheral
  • pain
  • diarrhoea
  • fatigue
  • pleural effusion
  • sepsis
  • tooth abscess
  • renal failure
  • stomatitis
  • cellulitis
60+:
  • drug ineffective
  • rheumatoid arthritis
  • weight decreased
  • arthralgia
  • cough
  • myocardial infarction
  • dyspnoea
  • asthenia
  • injection site pain
  • nausea

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Imuran and Enbrel?

Can you answer these questions?

More questions for: Imuran, Enbrel

You may be interested in these reviews

More reviews for: Imuran, Enbrel

On eHealthMe, Imuran (azathioprine) is often used to treat crohn's disease. Enbrel (etanercept) is often used to treat rheumatoid arthritis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.